Organigram Global's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 76.16.
Organigram Global's Days Inventory for the
three
months ended in Mar. 2026 was 279.16.
Organigram Global's Days Payable for the
three
months ended in Mar. 2026 was 150.31.
Therefore, Organigram Global's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 205.01.
Organigram Global (STU:0OG) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Organigram Global Cash Conversion Cycle Related Terms
Organigram Global Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Organigram Global's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0OG vs ZTS, UTHR: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Organigram Global's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organigram Global Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organigram Global's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Organigram Global's Cash Conversion Cycle falls into.
Organigram Global Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Organigram Global's Cash Conversion Cycle for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organigram Global (STU:0OG) has a Cash Conversion Cycle of 205.01 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Organigram Global and its competitors.
Is Organigram Global's Cash Conversion Cycle too high?
Organigram Global's current Cash Conversion Cycle is 205.01. The Drug Manufacturers industry median Cash Conversion Cycle is 145.87. Organigram Global's value of 205.01 is 40.5% above this industry median. Overall, Organigram Global has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organigram Global's Cash Conversion Cycle compare to ZTS and UTHR?
Organigram Global's Cash Conversion Cycle of 205.01 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.87. Organigram Global's value of 205.01 is 40.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.87, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organigram Global's current Cash Conversion Cycle of 205.01 is 40.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Organigram Global and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organigram Global's current Cash Conversion Cycle is 205.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organigram Global stock overvalued right now?
Based on GuruFocus' analysis, Organigram Global (STU:0OG) is currently considered Possible Value Trap. The stock's GF Value™ is €1.49, compared to a current price of €0.88 — trading 40.9% below its estimated fair value. The current Cash Conversion Cycle is 205.01 and 40.5% above the Drug Manufacturers industry median of 145.87. Organigram Global's overall GF Score™ is 61/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Organigram Global (STU:0OG), the current Cash Conversion Cycle is 205.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organigram Global (STU:0OG) Overvalued in 2026?
Based on GuruFocus' analysis, Organigram Global stock appears to be undervalued.
The current stock price of €0.88 is trading 40.9% below its estimated GF Value™ of €1.49.
GuruFocus considers Organigram Global to be Possible Value Trap.
Key valuation signals for STU:0OG:
Cash Conversion Cycle: 205.01
GF Value™: €1.49 vs. price of €0.88 (40.9% below fair value)
Industry Position: 40.5% above the Drug Manufacturers median
No single metric tells the full story. See the STU:0OG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
61GF Score
Get the complete analysis for STU:0OG
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0OG has been successfully added to your 
